Skip to main content

USPTO Publishes Four RNAi-Related Patent Applications: Mar 30, 2006

Premium

Title: Methods of Reducing an Immune Response

Number: 20060063733

Filed: Oct. 31, 2005

Inventor: Quiming Chu, Genzyme

"The invention relates to methods of reducing an immune response to a transgene product in a mammal by co-administration of a small-interfering ribonucleic acid molecule that temporarily inhibits or reduces transgene expression, wherein the siRNA is administered in an amount, and for a period of time, sufficient to reduce an immune response to the transgene product when it is expressed at therapeutic levels," the patent application's abstract states. "The … invention further relates to methods of administering siRNAs to a mammal to reduce an immune response to an immunogenic protein, such as an enzyme used in enzyme replacement therapy."


Title: In Vivo Inhibition of Hepatitis B Virus

Number: 20060063731

Filed: Sept. 26, 2005

Lead Inventor: David Lewis, Mirus

According to the patent application's abstract, the invention involves a process to "deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs," the abstract states.


Title: MicroRNA Vectors

Number: 20060063174

Filed: June 21, 2005

Lead Inventor: David Loyd Turner, University of Michigan

The invention "relates to gene silencing, and in particular to compositions of microRNA sequences and vectors and to methods of synthesizing such in vitro and in vivo, and to methods of using such to regulate gene expression," the patent application's abstract states.


Title: Detecting RNAi Using SELDI Spectrometry

Number: 20060063161

Filed: Sept.22, 2004

Lead Inventor: Reddy Gurucharan, Ciphergen Biosystems

The invention "relates to the fields of protein expression and molecular biology. In particular, the present invention includes methods for monitoring the levels of polypeptide inhibition caused by inhibitory nucleic acids," the patent application's abstract states.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.